Chagnac A, Gazit D, Zahavi I, Sela J, Levi J
Department of Nephrology, Hasharon Hospital, Petah Tiqva, Israel.
Miner Electrolyte Metab. 1989;15(5):291-4.
It has been shown in vitro that verapamil inhibits parathyroid hormone-induced bone resorption. To determine the effect of verapamil administration on bone histology in rats with chronic renal failure, male Wistar rats were divided into three groups: subtotally nephrectomized (SNX), SNX treated with verapamil, 8 mg/kg/day p.o. (SNX-V) and control (C). Thirteen weeks later, the mandibular condyle bone was studied by histomorphometry. When compared to C rats, SNX rats had active bone disease, with increased resorption parameters (resorption surface, active resorption surface, osteoclast number) and accelerated mineral appositional rate. These parameters improved with verapamil administration. When compared to C rats, SNX-V rats had decreased osteoid seam width and mineral appositional rate. Serum parathyroid hormone was similarly elevated in both uremic groups. These data suggest that verapamil administration improves active bone disease in rats with chronic renal failure and decreases bone formation.
体外实验表明,维拉帕米可抑制甲状旁腺激素诱导的骨吸收。为确定维拉帕米给药对慢性肾衰竭大鼠骨组织学的影响,将雄性Wistar大鼠分为三组:次全肾切除组(SNX)、接受维拉帕米治疗(8 mg/kg/天,口服)的次全肾切除组(SNX-V)和对照组(C)。13周后,采用组织形态计量学方法研究下颌髁突骨。与C组大鼠相比,SNX组大鼠存在活动性骨病,其吸收参数(吸收表面、活跃吸收表面、破骨细胞数量)增加,矿物质沉积速率加快。维拉帕米给药后这些参数有所改善。与C组大鼠相比,SNX-V组大鼠类骨质缝宽度和矿物质沉积速率降低。两个尿毒症组的血清甲状旁腺激素均同样升高。这些数据表明,维拉帕米给药可改善慢性肾衰竭大鼠的活动性骨病并降低骨形成。